PCM
NXTC icon

Prelude Capital Management’s NextCure NXTC Stock Holding History

Prelude Capital Management’s Portfolio NXTC Stock Details NXTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,525
Closed -$110K – 2107
2021
Q4 		$110K Sell
1,525
-3,592
-70% -$301K ﹤0.01% 1697
2021
Q3 		$414K Buy
+5,117
New +$449K 0.01% 994
2020
Q4 		– Sell
-92
Closed -$10K – 1775
2020
Q3 		$10K Buy
+92
New +$11.3K ﹤0.01% 1457

Other funds holding NXTC

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Prelude Capital Management's NXTC Position: Q1 2022 in Review

Prelude Capital Management sold out of NextCure (NXTC) in Q1 2022, closing a stake of 1,525 shares — an estimated $110K sold.

Prelude Capital Management first reported a position in NXTC in Q3 2020 and held it in 3 quarters. The position peaked at $414K in Q3 2021. 59 funds tracked by Wall St. Rank hold NXTC as of Q1 2022.

  • Prelude Capital Management reported no remaining NextCure position as of Q1 2022 after selling out during the quarter.
  • Prelude Capital Management sold 1,525 NextCure shares in Q1 2022, an estimated $110K.
  • Prelude Capital Management first reported a position in NextCure in Q3 2020 and held it in 3 quarters.
  • Prelude Capital Management's NextCure position peaked at $414K in Q3 2021.
  • 59 funds tracked by Wall St. Rank held NextCure as of Q1 2022.

Based on Prelude Capital Management's 13F filing for Q1 2022, filed 16 May 2022.